Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Treasury Stock: NT$-44.97 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7427 Great Novel Therapeutics Biotech & Medicals ROCO:7427
50 GF Score
Price NT$72.60
GF Value NT$107.92
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Great Novel Therapeutics Biotech & Medicals Treasury Stock?

Great Novel Therapeutics Biotech & Medicals ROCO:7427 -0.95% 50 Treasury Stock is NT$-44.97 Mil as of Jun. 2026. GuruFocus rates ROCO:7427 with a GF Score™ of 50/100 and a GF Value™ of NT$107.92 (Possible Value Trap). The stock has 4 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Great Novel Therapeutics Biotech & Medicals's treasury stock for the quarter that ended in Jun. 2026 was NT$-44.97 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Great Novel Therapeutics Biotech & Medicals Treasury Stock Historical Data

* Premium members only.

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals Treasury Stock Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -44.97

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -29.97 -44.97 -44.97
ROCO:7427
50GF Score
Great Novel Therapeutics Biotech & Medicals ROCO:7427
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Great Novel Therapeutics Biotech & Medicals Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of NT$-44.97 Mil mean?
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a Treasury Stock of NT$-44.97 Mil as of Jun. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Great Novel Therapeutics Biotech & Medicals and its competitors.
Is Great Novel Therapeutics Biotech & Medicals' Treasury Stock too high?
Great Novel Therapeutics Biotech & Medicals' current Treasury Stock is NT$-44.97 Mil. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' Treasury Stock compare to VRTX and REGN?
Great Novel Therapeutics Biotech & Medicals' Treasury Stock of NT$-44.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Great Novel Therapeutics Biotech & Medicals and its competitors. Great Novel Therapeutics Biotech & Medicals's current Treasury Stock is NT$-44.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Possible Value Trap. The stock's GF Value™ is NT$107.92, compared to a current price of NT$72.60 — trading 32.7% below its estimated fair value. The current Treasury Stock is NT$-44.97 Mil. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current Treasury Stock is NT$-44.97 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?

Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be undervalued. The current stock price of NT$72.60 is trading 32.7% below its estimated GF Value™ of NT$107.92. GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Possible Value Trap.

Key valuation signals for ROCO:7427:

  • Treasury Stock: NT$-44.97 Mil
  • GF Value™: NT$107.92 vs. price of NT$72.60 (32.7% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Great Novel Therapeutics Biotech & Medicals Business Description

Address No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
50GF Score

Get the complete analysis for ROCO:7427

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$72.60
Price
NT$107.92
GF Value